Madrigal Pharmaceuticals, Inc., planned to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on January 31, 2022. Madrigal's lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-ß selective agonist that is currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
273.7 USD | -2.23% |
|
-6.57% | +18.30% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.30% | 5.83B | |
+20.17% | 126B | |
+24.67% | 118B | |
+23.52% | 27.87B | |
-17.74% | 20.95B | |
-16.45% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- MDGL Stock
- News Madrigal Pharmaceuticals, Inc.
- Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom